175P: ALK Positive Lung Cancer: Clinical Profile and Outcomes in a Developing Country

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(16)30285-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

Clinical Feature and Survival Outcomes of Lung Cancer With ALK Mutation Positive and Treated With Crizotinib, Single Centre Experience

Acta Oncologica Turcica
2019English

ALK Is a Critical Regulator of the MYC-signaling Axis in ALK Positive Lung Cancer

Oncotarget
Oncology
2018English

P1.02-05 ALK Positive Lung Cancer: Patient Engagement and Partnership

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research
Cancer ResearchOncology
2016English

Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

P087 TNM Staging Inversely Correlates With Age in ALK-positive Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy